Dyne Therapeutics, Inc.
NASDAQ:DYNBiotechnology
Healthcare
$16.03 +1.97%
+$0.38 today
- Market cap
- $3.00B
- Beta
- 1.08
- P/E (TTM)
- -7.2
- EPS (TTM)
- -$2.74
52W Low $8.06High $25.00
Volume 2.44M
Average 1.71M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$403.21M
FY 2025 · Annual
Investing Cash Flow
-$28.75M
FY 2025 · Annual
Financing Cash Flow
$890.31M
FY 2025 · Annual
+9.9% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (149.29M) | (168.1M) | (235.94M) | (317.42M) | (446.21M) |
| Depreciation & Amortization | 1.09M | 1.68M | 1.67M | 1.67M | 2.05M |
| Deferred Income Tax | 2.59M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 17.54M | 15.18M | 19.97M | 45.86M | 45.85M |
| Change in Working Capital | 9.26M | (5.38M) | 26.31M | (19.49M) | (3.4M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 13.7M | (1.24M) | 22.97M | (8.96M) | 8.25M |
| Other Working Capital | (4.45M) | (4.14M) | 3.34M | (10.54M) | (11.65M) |
| Other Non-Cash Items | (746K) | 2.97M | (173K) | (3M) | (1.49M) |
| Operating Cash Flow | (119.56M) | (153.65M) | (188.16M) | (292.37M) | (403.21M) |
| Capital Expenditures | (3.62M) | (3.07M) | (729K) | (2.38M) | (1.92M) |
| Acquisitions (Net) | 8K | 34K | 0 | 0 | 0 |
| Purchases of Investments | (236.72M) | (121.18M) | (44.26M) | (317.44M) | (180.53M) |
| Sales of Investments | 102.45M | 211.45M | 128.3M | 115.71M | 172.46M |
| Other Investing Activities | (8K) | (34K) | 0 | 35K | (18.76M) |
| Investing Cash Flow | (137.89M) | 87.2M | 83.31M | (204.08M) | (28.75M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 147.7M |
| Common Stock Issued | 157.24M | 36.86M | 52.37M | 773.05M | 742.61M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 584K | 529K | 1.95M | 36.84M | 0 |
| Financing Cash Flow | 157.82M | 37.39M | 54.32M | 809.9M | 890.31M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (99.63M) | (29.05M) | (50.53M) | 313.45M | 458.35M |
| Free Cash Flow | (123.18M) | (156.71M) | (188.89M) | (294.75M) | (405.13M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$446.2M
+ D&A$2.0M
+ Stock-Based Comp$45.9M
+ Deferred Tax$0
- Working Capital-$3.4M
- Other Non-Cash-$1.5M
= Operating Cash Flow-$403.2M
- Capex-$1.9M
= Free Cash Flow-$405.1M
Analysis
FY2025 free cash flow is -$405.1M. FCF conversion is 90.8% of net income. Operating cash flow was -$403.2M, with capex of -$1.9M. The largest bridge item is Stock-Based Comp at $45.9M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 22, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 6, 2026 | |
| 8-K | Current report | Sep 29, 2026 |
Does DYN generate free cash flow?
Dyne Therapeutics, Inc. (DYN) generated -$405.13M of free cash flow in fiscal 2025.
How much operating cash flow does DYN produce?
Operating cash flow was -$403.21M, before capital expenditures of $1.92M.
Continue the stock analysis
Jump to another research area for this company.